09
June

08:00 AM BST

Medicinal Chemistry

Strategy Meeting Europe 2022

The premier meeting for European Medicinal Chemistry professionals

Radisson Blu Hotel, Stansted Airport

Remove

A MEETING EXPERIENCE UNLIKE ANY OTHER

Fresh Medicinal Chemistry Insights

Tired of the same conference experience? Real discussions and genuine networking are often promised, but not always delivered. Proventa International’s R&D Strategy Meetings are designed to avoid the pitfalls of a typical conference, by providing the right environment to make those important connections through interactive roundtable discussions, exclusive networking and keynote panel debates. Join Medicinal Chemistry professionals from across Europe, to discover new insights and take your company’s mission to the next level.

What makes our strategy meetings unique?

Roundtable Discussions

Intimate discussions led by renowned industry experts. Have your voice heard and debate alongside like-minded life science executives.

Unrivalled Networking

With senior delegation from big pharma and innovative biotech from across Europe, you can network with peers from different locations, all in one place.

Personalised Agenda

Choose the topics that matter to you. Reserve your place at the roundtable discussions and ensure your whole day delivers the insights you need to hear.

Solutions to your Problems

We’ve partnered with the best solution providers to solve your biggest challenges. Engage in pre-arranged, private meetings to address your specific needs and find a tangible solution.

Industry Researched Topics

We guarantee our agenda is up-to-date and mission critical because its designed by you. We speak to our extended network of senior decision makers to ensure the most important topics are discussed.

Senior Decision Makers

The entire strategy meeting is specifically tailored to the needs and challenges of senior life science professionals. Discover how your peers are dealing with the same challenges as you.

Become an official strategy meeting partner

Whatever your business needs, we can help. Get in touch for partnering opportunities

I’D LIKE TO PARTNER

Press play to hear what your colleagues had to say...

See the full agenda and facilitator line-up

Download the strategy meeting brochure for full details

DOWNLOAD THE BROCHURE

Meet Our 2022 Speakers

Our panel of facilitators play a key role in shaping the agenda for the day. See who will be bringing their expertise to the table at our 2022 Medicinal Chemistry strategy meeting.

Matthew Segall

CEO Optibrium

Scott McDonald

Director of Business Development Optibrium

Dave Madge

VP WuXi Discovery Services WuXi AppTec

Andreas Bender

Professor, Molecular Informatics University of Cambridge

Roland Bürli

VP, Chemistry Cerevance

Ian Churcher

Chief Scientific Officer Amphista Therapeutics Limited

Werngard Czechtizky

Executive Director, Head of Medicinal Chemistry, Respiratory and Immunology AstraZeneca

Matthew Fyfe

Head of Chemistry and Intellectual Property Sitryx Therapeutics

Abdul Hamid Merii

Machine Learning Engineer Silence Therapeutics

Robert Heald

VP, Chemistry Artios Pharma

Robert Heald is a Medicinal Chemist with over 20 years of industrial experience and currently VP of Chemistry at Artios Pharma, a leading clinical stage UK Biotech company focussed on the exploiting therapeutic opportunities in the DNA damage response for the treatment of cancer. 
Before joining Artios Rob was a Director of Chemistry at Argenta Discovery (latterly Charles River) where he managed a group of over 30 chemists and led teams and projects in collaborations with a wide range of institutions from Universities to large Biotech and Pharma. These collaborations included 10 years with Genentech and 5 years with Chiesi. During this time his teams were responsible for the discovery of 6 clinical candidates for oncology and respiratory indications, the most advanced of which is now in Phase III clinical studies.
Since joining Artios in 2016 shortly after Series A fundraising Rob has led the medicinal chemistry team responsible for delivering the first human DNA polymerase inhibitor to enter clinical trials, ART4215.
Rob is an author or inventor of over 50 publications and patents and holds a BSc and PhD from the University of Nottingham.

György Keseru

Principal Investigator Research Centre for Natural Sciences

Guido Koch

Chief Executive Officer Amphilix

Guido Koch is a board member of SynpleChem and co-founder and CEO of <a href="https://www.amphilix.com/">Amphilx</a>. From 2018 to 2020, Guido was the COO of Topadur Pharma and before a Director in Global Discovery Chemistry at Novartis.
During his career in drug discovery and development, Guido has lead projects in different phases from target identification to early clinical stage including multiple kinase inhibitors. Highlights from >20 years of experience in pharmaceutical industry include significant contributions to one marketed product and 8 clinical candidates.
Guido has built a strong network with academia and the CRO community, which allows him to support research programs by external knowledge, new technology and resources. His research has culminated in >45 scientific publications and 10 patent applications.
Educated at ETH Zürich, he received his Diploma in Chemistry and Biochemistry in 1991, followed from a PhD from the University of Basel. After a postdoc at Caltech, he joined Novartis in 1997.

Pierre Morieux

Chemistry Product Marketing Manager PerkinElmer

Garry Pairaudeau

Chief Technology Officer Exscientia

Garry Pairaudeau is currently Head of Hit Discovery at AstraZeneca; the group comprising HTS, Comp Chem, Virtual screening and DEL is responsible for generating high quality starting points for AstraZeneca. In addition, the group works extensively with academic centres of excellence through open innovation and strategic collaborations with groups such as MRC, CRUK, Life Arc and many others to help support academic drug discovery. Garry also chairs the Global Chemistry Leadership team in AstraZeneca responsible for chemistry strategy and has been particularly active in building Automation and Machine learning capabilities.
He has experience leading projects through all phases of Drug Discovery contributing to multiple clinical candidates in the respirator,y inflammation and CV areas. He has a long standing interest in lead generation, innovation, in chemistry, hit identification and diversity screening. Prior to taking up his current position in 2012 he was Director of Chemistry for the cardiovascular research area at Alderley Park.
Specialties: Medicinal Chemistry 
Lead Generation 
Leadership, Strategy and Change Management 
Innovation and Culture Change 
Building and managing external relationships

Graham Simpson

SVP, Drug Discovery Dunad Therapeutics

A creative and passionate scientific leader with a strong track record of establishing, driving and delivering innovative drug discovery programs in pharma and biotech. Keen interest in, and appreciation of the broader business challenges facing the pharmaceutical industry; well networked throughout the global pharmaceutical and academic communities. Experienced and ambitious drug discovery leader with 12 years pharmaceutical industry experience. Recognised platform and programme leader, delivering multiple breakthrough innovations and successful discovery milestones. Broad therapeutic area experience and track record of innovation and delivery
Specialties: Chemistry Department Head/Leader, PROTACS, macrocyclic peptides, phenotypic screening, parallel synthesis, complex organic total syntheses, HTS analysis, rational medicinal chemistry and drug design, knowledge-based design, managing CRO workplans, innovative modalities, next-generation in-silico design, artificial intelligence.

Marie Wikstrom Lindholm

SVP, Head of Molecular Design Silence Therapeutics

Quick Links

Want to find out more?

Find out more details about our Strategy Meetings and other news and events.

Europe

USA East

USA West

Webinars

Dinners & Spotlights

R&D

R&D Europe

Bioinformatics & Drug Discovery Biology Strategy Meeting Europe 2025

Medicinal Chemistry

Strategy Meeting Europe 2022

<img class="lazy" decoding="async" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://proventainternational.com/wp-content/uploads/2020/12/location.png" >Radisson Blu Hotel, Stansted Airport

Fresh Medicinal Chemistry Insights

What makes our strategy meetings unique?

Roundtable Discussions

Unrivalled Networking

Personalised Agenda

Solutions to your Problems

Industry Researched Topics

Senior Decision Makers

Become an official strategy meeting partner

Press play to hear what your colleagues had to say...

See the full agenda and facilitator line-up

Meet Our 2022 Speakers

Matthew Segall

Scott McDonald

Dave Madge

Andreas Bender

Roland Bürli

Ian Churcher

Werngard Czechtizky

Matthew Fyfe

Abdul Hamid Merii

Robert Heald

György Keseru

Guido Koch

Pierre Morieux

Garry Pairaudeau

Graham Simpson

Marie Wikstrom Lindholm

Our 2022 Co-Hosts

Want to find out more?

Select days you wish to attend You can add multiple days

Daily Delegate Rate includes:

VAT Excluded

Select days you wish to attend You can add multiple days

Pass includes:

VAT Excluded

About You

Your Address

About Your Company

This is required field*

Bone/Osteoporosis

Immunology

Orthopaedics

Cardiovascular

Infectious diseases

Pulmonology

CNS

Inflammation

Psychiatry

Dermatology

Internal diseases

Respiratory

Diabetes

Metabolic diseases

Rheumatology

Endocrinology

Nephrology

Surgery

ENT

Neurology

Urology

Gastroenterology

Oncology

Vaccines

Haematology

Ophthalmology

Thrombosis

Rare Diseases

This is required field*

Radisson Blu Hotel, Stansted Airport